GlassScriptPhysician profile
Christopher L Mauldin
NPI 1902831837
$5,507.41
in general payments reported to CMS, 2019-2025
31 companies · $72.60 in 2025
The $72.60 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,083 · 2020: $1,053 · 2021: $1,184 · 2022: $625 · 2023: $907 · 2024: $583 · 2025: $72.60.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,562.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,561.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,059.43 | 2020-2025 | Xifaxan |
| Abbvie INC. | $629.88 | 2020-2025 | |
| Novo Nordisk INC | $473.32 | 2019-2024 | Ozempic, Rybelsus |
| Merz North America, INC. | $436.80 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $424.68 | 2019-2025 | Farxiga, Airsupra, Lokelma |
| Astellas Pharma US INC | $370.83 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $269.52 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $214.90 | 2019-2022 | |
| Lilly USA, LLC | $188.91 | 2021-2024 | Mounjaro, Zepbound, Jardiance |
| Otsuka America Pharmaceutical, INC. | $185.46 | 2019-2024 | Rexulti, Nuedexta |
| Allergan, INC. | $165.50 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $150.03 | 2019-2024 | |
| Pfizer INC. | $128.73 | 2019-2023 | |
| Amarin Pharma, INC. | $119.86 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $108.17 | 2019-2021 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $106.82 | 2020-2023 | Trelegy Ellipta, Shingrix, Arexvy |
| Amgen INC. | $78.71 | 2019-2024 | Prolia, Evenity, Otezla |
| Takeda Pharmaceuticals U.S.A., INC. | $66.01 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $44.22 | 2019-2021 | |
| Daiichi Sankyo INC. | $42.12 | 2021 | |
| Ibsa Pharma INC. | $34.19 | 2022-2023 | Tirosint, Licart |
| Neuronetics, INC. | $33.25 | 2019 | |
| Avanir Pharmaceuticals, INC. | $30.26 | 2021-2022 | |
| Abbott Laboratories | $25.94 | 2021 | |
| Xeris Pharmaceuticals, INC. | $22.85 | 2023 | Gvoke Hypopen |
| Biohaven Pharmaceutical Holding Company LTD. | $17.70 | 2022 | |
| Medtronic, INC. | $17.54 | 2022 | |
| Lundbeck LLC | $17.17 | 2023 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $16.27 | 2024 | |
| Endogastric Solutions, INC | $14.50 | 2022 | |
| Sanofi-Aventis U.S. LLC | $13.84 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Mauldin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.